Understanding how lung cancer affects COVID-19 vulnerability through antibody analysis
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
This study is looking at how lung cancer affects the way patients respond to COVID-19 and vaccines, so we can find better ways to protect them during the pandemic.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10855044 on NIH RePORTER |
What this research studies
This research investigates why lung cancer patients are more vulnerable to severe outcomes from COVID-19 by analyzing their antibody responses to the virus and vaccines. It involves comparing the immune responses of lung cancer patients with those of healthy individuals, as well as studying how the cancer itself and its treatments may affect these responses. The goal is to gather critical information that can help develop effective vaccination strategies and protective measures for lung cancer patients against COVID-19.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with lung cancer who may be at increased risk for severe COVID-19 outcomes.
Not a fit: Patients without lung cancer or those who are not at risk for severe COVID-19 outcomes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies and protective measures specifically tailored for lung cancer patients, enhancing their safety against COVID-19.
How similar studies have performed: Other research has shown that understanding immune responses in cancer patients can lead to better treatment strategies, indicating potential success for this approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Hirsch, Fred R — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hirsch, Fred R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.